TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04716998

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MesenCure
Description: Three administrations of MesenCure in addition to standard care
Study: NCT05734352

Intervention type: OTHER
Intervention: Questionnaire
Description: Completion of the patient reported experience measurements (PREMs) questionnaire
Study: NCT06377046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated pacing
Description: The lower rate of the pacemaker will be programmed to 80 bpm in DDDR mode with mode switch to DDIR mode.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Current standard of care
Description: The lower rate of the pacemaker will be programmed to the current standard of care which is 60 bpm in DDDR mode with mode switch to DDIR mode.
Study: NCT05014646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Given PO
Study: NCT06092619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vojta Therapy
Description: The therapist applied pressure to defined zones on the body whilst positioned in prone, supine and side lying, where the stimulus leads to automatically and involuntarily complex movement.The parents were also instructed on at least one of the exercises from the first session, after the initial assessment. The home program was progressively increased and supervised until the three therapy positions were mastered, during weekly or fortnightly follow ups. The recommended dose was four times per day at home, in session no longer than 15-20 minutes; however, the daily frequency of each family due to different availability was also taken in account. The frequency of the dose was divided into 3 groups: families who could carry on therapy a) three times per day, b) four times per day, c) one or two times per day, d) less than seven times per week or therapy at the clinic

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy:
Description: Conventional physiotherapy intervention included goal-directed functional training based on tasks. These motor skills will be performed in enhanced and adapted settings, but as similar as possible to the usual activities of daily living. Family and children participated in the goal setting, and the approach will focus on overcoming the limitations of the activities to reach these, instead of the modification of the movement patterns. This intervention is founded in motor learning and behavioral neuroscience, focusing on participation and activity acquisition.
Study: NCT04627506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral NIRS (Masimo, O3TM Regional Oximetry)
Description: Bilateral NIRS will be used to measure rSO2 intraoperatively. The NIRS electrodes will be placed on fronto-temporal area and baseline values of rSO2 obtained according to manufacturer's guidelines in the operating room prior to induction of anesthesia. The NIRS screen will be concealed in the control group to ensure blinding.
Study: NCT06364670

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncture will be performed at acupoints including TE17 (Yifeng), SI19 (Tinggong), GB2 (Tinghui), TE5 (Waiguan), TE3 (Zhongzhu), ST36 (Zusanli ), KI3 (Taixi), and etc.
Study: NCT05445128

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGTA-145
Description: MGTA-145 will be administered as an IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGTA-145
Description: MGTA-145 will be administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: 240 µg/kg administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: 240 µg/kg administered subcutaneously
Study: NCT05451459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12-week FMS Intervention
Description: 4 virtual workshops (2-3 hours each) covering topics of 1) Sensory Integration, 2) Communication, 3) Physical activity, and 4) Sports (during intervention)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activities & Activity Booklets (via FitFamilies app)
Description: expected to engage in physical activity at least 3 hours per week, virtual workshops provide them with resources to engage in Physical activity

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical Activities & Activity Booklets (via FitFamilies app)
Description: expected to engage in physical activity at least 3 hours per week, virtual workshops provide them with resources to engage in Physical activity
Study: NCT06414837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR091506 tablets + placebo of febuxostat tablets
Description: HR091506 tablets 20mg/ 40mg/ 60mg/80mg qd + placebo of febuxostat tablets 20mg/ 40mg/ 60mg/80mg qd, from Week 1 to 36.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: febuxostat tablets + placebo of HR091506 tablets
Description: febuxostat tablets 20mg/ 40mg/ 60mg/80mg qd + placebo of HR091506 tablets 20mg/ 40mg/ 60mg/80mg qd . from Week 1 to 36.
Study: NCT05237349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: 300mg,sc,d1,Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2, iv,d1,Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: 40mg/m2, op,bid,d1-14,Q3W
Study: NCT01437280

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CGTG-102
Description: VP=virus particle~Dose Level 1: 3x10\^10 VP/injection~Dose Level 2: 1x10\^11 VP/injection~Dose Level 3: 3x10\^11 VP/injection~Patients will receive 4 administrations of CGTG-102 (on days 1, 4, 8, 15).~Escalation to the next dose level will occur when the safety of all 4 administrations has been evaluated at day 43 on all patients in the preceding dose level.~The total dose will be injected into up to 10 tumors injectable by either direct visualization/palpitation and/or ultrasound. Typically, the largest safely injectable tumors are chosen.~Injections will be performed by a radiologist or other trained physician. Injections will be planned based on the baseline PET-CT: only PET-positive tumors or tumor regions should be injected. Injection needles designed for percutaneous insertion into tissues will be used.
Study: NCT05998122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nCRT → (CapeOX+Sintilimab)×6 → Surgery/W&W
Description: Radiation: Long-course chemoradiotherapy is delivered in 50 Gy/25 fractions with concurrent Capecitabine (825mg/m2, P.O. Bid, 5d/w).~Drug: CapeOX (Capecitabine 1000mg/m2, P.O. Bid, d1-d14, q3w; Oxaliplatin 130mg/m2, i.v., d1, q3w), and Sintilimab (200mg, i.v. , d1).~Surgical Approach: TME surgery, The surgical approach can be open, laparoscopic or robotic depending on the patient.
Study: NCT01418430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP-daclizumab
Study: NCT05189470

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inforatio technique
Description: Inforatio technique is a novel minimal invasive procedure where small cuts are made on wound beds with punch biopsy tools near the wound edges but without involving wound edge epithelia. Inforatio technique is applied after the wound has been surgically debrided for slough and devitalized tissue.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care of the respective outpatient clinics
Description: Usual care of the DFUs includes local wound care and offloading treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care of the respective outpatient clinics
Description: Usual care of the DFUs includes local wound care and offloading treatment.
Study: NCT04714164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy
Description: Therapy will be delivered weekly for 8 weeks by Zoom.
Study: NCT05676502

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AIRVO 2
Description: Patients with chronic obstructive pulmonary disease and chronic respiratory failure use Nasal High Flow therapy during daytime sessions of 1.5 h.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AIRVO 2
Description: Patients with chronic obstructive pulmonary disease and chronic respiratory failure use Nasal High Flow therapy during daytime sessions of 1.5 h.
Study: NCT05057663

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin and 5-fluorouracil
Description: In the bleomycin-treated group, bleomycin vial will be diluted first with 5 ml distilled water At time of treatment session 2 ml of lidocaine 2% and 1 ml of the bleomycin stock solution will be taken in 100-unite insulin syringe. Thus, the working bleomycin solution will be used in treatment 1 mg/ml. The bleomycin solution will be injected intralesional till blanching of the wart will be occurred. The amount of injection ranging from 0.2, 0.5, 1 ml according to size of warts; (5 mm, 10 mm, \>10 mm) maximum for 1 ml in single wart and 2ml in treatment session. Treatment session will be done every two weeks maximum four sessions.~In 5-fluorouracil treated group, 5-fluorouracil vial ( 1 ml of 50 mg/ml 5-FU will be mixed with 0.25 ml of lidcaine 2% Every wart will be injected with 0.1 ml of the previous mixture into it base using an insulin syringe till blanching of the warts maximum 2ml of 5-FU per session. Treatment session will be done every two week for maximum 6 sessions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin and 5-fluorouracil
Description: In the bleomycin-treated group, bleomycin vial will be diluted first with 5 ml distilled water At time of treatment session 2 ml of lidocaine 2% and 1 ml of the bleomycin stock solution will be taken in 100-unite insulin syringe. Thus, the working bleomycin solution will be used in treatment 1 mg/ml. The bleomycin solution will be injected intralesional till blanching of the wart will be occurred. The amount of injection ranging from 0.2, 0.5, 1 ml according to size of warts; (5 mm, 10 mm, \>10 mm) maximum for 1 ml in single wart and 2ml in treatment session. Treatment session will be done every two weeks maximum four sessions.~In 5-fluorouracil treated group, 5-fluorouracil vial ( 1 ml of 50 mg/ml 5-FU will be mixed with 0.25 ml of lidcaine 2% Every wart will be injected with 0.1 ml of the previous mixture into it base using an insulin syringe till blanching of the warts maximum 2ml of 5-FU per session. Treatment session will be done every two week for maximum 6 sessions
Study: NCT04808817

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: calorimetry, impedance measurement at baseline and after 3 months of treatment
Description: biobanking (30ml) for cytokines and complement dosages at baseline and after 3 months of treatment calorimetry and impedance measure will be collected at baseline and after 3 months of ICI treatment
Study: NCT06278792

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diuretic protocol
Description: Nurse-led natriuresis-guided protocol based on a bedside urinary sodium result

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Diuretic therapy at the discretion of the physician
Study: NCT04816474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online education and Phone Counseling Service
Description: Online education total of 6 times for 6 weeks. Phone Counseling Service total of 6 times for 6 weeks
Study: NCT05177614

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Upper-level multiple micronutrient-fortified bouillon cube
Description: 80 µg/g Folic acid 1.2 µg/g Vitamin B12 3 mg/g Zinc (ZnO) 4 mg/g Iron (FePP/citric acid/trisodium citrate) 200 µg/g Vitamin A (retinyl palmitate) 30 µg/g Iodine (KIO3)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lower-level multiple micronutrient-fortified bouillon cube
Description: 28.8 µg/g Folic acid 0.288 µg/g Vitamin B12 1.68 mg/g Zinc (ZnO) 1.3 mg/g Iron (FePP/citric acid/trisodium citrate) 96 µg/g Vitamin A (retinyl palmitate) 30 µg/g Iodine (KIO3)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Iodine-fortified bouillon cube
Description: 30 µg/g Iodine (KIO3)
Study: NCT06212297

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: LX101
Description: Subretinal administration of LX101 to the contralateral, previously uninjected eye
Study: NCT04959396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IUB SEAD
Description: The investigative device, the IUB SEAD™, is a novel spherical endometrial ablation device developed to allow for simple, office-based chemical EA to treat benign causes of the symptom of HMB
Study: NCT04498715

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OSTEOSYNTHESIS
Description: Routine procedure for anesthesia and infection prophylaxis according to the clinics routines will be followed. The patient is supine with the fractured leg positioned in traction table. The biplanar x-ray device is moved and adjusted for proper simultaneous AP and lateral view. Hip region is washed and dressed in sterile draping's. Using standard proximal femur osteosynthesis technique 2.0 mm diameter Kirschner wire is placed in the middle zone of the femoral neck in AP and lateral view. The canal is opened using 6 mm drill bit and measured length of dynamic hip screw is placed in the femoral head and neck.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OSTEOSYNTHESIS
Description: Routine procedure for anesthesia and infection prophylaxis according to the clinics routines will be followed. The patient is supine with the fractured leg positioned in traction table. The biplanar x-ray device is moved and adjusted for proper simultaneous AP and lateral view. Hip region is washed and dressed in sterile draping's. Using standard proximal femur osteosynthesis technique 2.0 mm diameter Kirschner wire is placed in the middle zone of the femoral neck in AP and lateral view. The canal is opened using 6 mm drill bit and measured length of dynamic hip screw is placed in the femoral head and neck.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Zoledronic acid (ZA), is a bisphosphonate, and has been shown to reduce the risk of hip fracture by 41% in post-menopausal women. For systemic injection, 4 mg (as per clinical protocol) will be injected intravenously 1-2 weeks after surgery. For local delivery, 1 or 2 mg Zoledronic Acid will be added to 5 or 10 mg CERAMENT BVF during mixing and the mixture will be injected.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: Zoledronic acid (ZA), is a bisphosphonate, and has been shown to reduce the risk of hip fracture by 41% in post-menopausal women. For systemic injection, 4 mg (as per clinical protocol) will be injected intravenously 1-2 weeks after surgery. For local delivery, 1 or 2 mg Zoledronic Acid will be added to 5 or 10 mg CERAMENT BVF during mixing and the mixture will be injected.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CERAMENT BONE VOID FILLER (BVF)
Description: CERAMENT™\|BONE VOID FILLER is a synthetic, injectable, osteoconductive bone void filler. CERAMENT™I is biphasic, consisting of 60% calcium sulfate and 40% hydroxyapatite mixed with the radio-opacity enhancing component CERAMENT™\|C-TRU (iohexol 300 mg iodine/ml), which allows bone in-growth after curing. The high injectability of CERAMENT™ allows transcortical administration and ensures good intraosseous spread. In this trial, CERAMENT BVF paste will be injected by a sterilized metal needle (2-3 mm diameter and 15 cm length) through the hollow dynamic hip screw.
Study: NCT05889715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Green Wellness Program: Plants-2-Plate
Description: A 6-month, intensive interprofessional program focused on a WFPB predominant eating pattern
Study: NCT06089278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300mg of TQH2722 injection
Description: TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600mg of TQH2722 injection
Description: TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQH2722 injection matching placebo
Description: Placebo without active substance.
Study: NCT06543901

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Submuscular plating
Description: the patient was fixed with a submuscular plate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traction and casting
Description: the patient was placed on a traction with a thomas splint and then was casted with a hip spica
Study: NCT04842097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Description: An online mindfulness-based stress reduction intervention will be administered in a group format of maximum 15 participants, once a week for 120 minutes for 8 weeks by an experienced therapist trained in MBSR. Sessions will include sitting and lying meditation, hatha yoga and a body scan where attention is sequentially focused on different parts of the body. Individual autonomous practice between 30-45 minutes, 6 times / week will also be recommended. To support individual autonomous practice, a daily diary and two guided videos (around 35 minutes/each) were created.
Study: NCT05003427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-04
Description: 68Ga-FAPI-04 were injected into the patients before the PET/CT scans
Study: NCT05754853

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MRG002
Description: Administrated intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel Injection
Description: Administrated intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Injection
Description: Administrated intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride for Injection
Description: Administrated intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium Injection
Description: Administrated intravenously
Study: NCT06040411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Acupressure was applied to each point for 2 minutes and the total application time was 15 minutes on average (for 5 points). During the application, the most appropriate position in which the individual would be comfortable was preferred, taking into account the privacy of the individual. First of all, the supine position was preferred, and alternatively, the sitting position was preferred. At the end of the application, it was ensured that the person was in a position that he/she was comfortable.
Study: NCT06079385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Description: Acupuncture treatment with needles
Study: NCT06462053

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy
Description: Short-course radiotherapy: 25Gy/5Fx

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody (Toripalimab)
Description: Toripalimab 240mg d1 q3w

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Long-course radiotherapy
Description: Long-course radiation: 50Gy/25Fx

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: 130mg/m2 d1 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: 130mg/m2 d1 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Xeloda

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Xeloda
Study: NCT05651100

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 and CD22 targeted CAR-T cells
Description: CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (300 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In sequential CAR-T clinical trials, CAR-T cells will be given.（anti-CD19 CAR-T first, then anti-CD22 CAR-T).
Study: NCT05110768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic AVNU
Description: Triferic AVNU is an iron salt that is approved for the maintenance of Hgb in chronic kidney disease patients on hemodialysis. It is experimental in this study because it has not yet been approved for patients receiving home infusion therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal TPN solution without FPC on alternate days with TPN supplemented with multivitamins.
Study: NCT04837937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver vs. Patient [Beginner]
Description: Participants will be assigned a 'Caregiver vs. Patient' \[Beginner\] online negotiation exercise. All participants will complete this exercise, so it will serve as the constant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver vs. Patient [Beginner]
Description: Participants will be assigned a 'Caregiver vs. Patient' \[Beginner\] online negotiation exercise. All participants will complete this exercise, so it will serve as the constant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver vs. Patient [Beginner]
Description: Participants will be assigned a 'Caregiver vs. Patient' \[Beginner\] online negotiation exercise. All participants will complete this exercise, so it will serve as the constant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver vs. Patient [Beginner]
Description: Participants will be assigned a 'Caregiver vs. Patient' \[Beginner\] online negotiation exercise. All participants will complete this exercise, so it will serve as the constant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver vs. Patient [Beginner]
Description: Participants will be assigned a 'Caregiver vs. Patient' \[Beginner\] online negotiation exercise. All participants will complete this exercise, so it will serve as the constant.
Study: NCT04300075

Intervention type: DEVICE
Intervention: CUSABT
Description: Subject receives use of the CUSA Clarity Bone Tip product during cranial skull base bone removal surgery
Study: NCT03438500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Extracorporeal Shockwave Therapy (Modulith SLC)
Description: 40 - 60 spots per visit (200 shots/spot) at Energy Level 3
Study: NCT05790330

Intervention type: DRUG
Intervention: Methotrexate
Description: As per usual standard of care

Intervention type: DRUG
Intervention: Dupilumab
Description: As per usual standard of care